Harley PoMMom
02-23-2011, 06:01 PM
Contact:
Elizabeth Likly
Kovak-Likly Communications
203-762-8833; elikly@klcpr.com
UPSHER-SMITH LABORATORIES ANNOUNCES EXPANSION OF
VOLUNTARY NATIONWIDE RECALL
Affected products include Amantadine, Amlodipine, Androxy, Baclofen, Bethanechol,
Jantoven® and Oxybutynin
FOR IMMEDIATE RELEASE - February 18, 2011 - Upsher-Smith Laboratories, Inc., of Maple Grove, Minnesota is voluntarily expanding its previously announced recall of Jantoven® Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010. The company is initiating the recall as a precautionary measure after a bottle labeled as Jantoven® Warfarin Sodium, USP, 3 mg Tablets was found by a retail pharmacy to contain tablets at a higher, 10 mg strength.
At Upsher-Smith, patient safety is of foremost concern. The substitution of warfarin, or any other product, may lead to a change in the therapeutic effect of the intended drug.
Consistent, continuous dosing of any product is necessary for optimal care for many ill patients. Patients should check with their health care provider regarding the appropriateness of their current therapy prior to making any change.
Please see this link for full details: http://www.upsher-smith.com/news/newsarticles/2011_02_18-Expanded-Recall.pdf
Elizabeth Likly
Kovak-Likly Communications
203-762-8833; elikly@klcpr.com
UPSHER-SMITH LABORATORIES ANNOUNCES EXPANSION OF
VOLUNTARY NATIONWIDE RECALL
Affected products include Amantadine, Amlodipine, Androxy, Baclofen, Bethanechol,
Jantoven® and Oxybutynin
FOR IMMEDIATE RELEASE - February 18, 2011 - Upsher-Smith Laboratories, Inc., of Maple Grove, Minnesota is voluntarily expanding its previously announced recall of Jantoven® Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010. The company is initiating the recall as a precautionary measure after a bottle labeled as Jantoven® Warfarin Sodium, USP, 3 mg Tablets was found by a retail pharmacy to contain tablets at a higher, 10 mg strength.
At Upsher-Smith, patient safety is of foremost concern. The substitution of warfarin, or any other product, may lead to a change in the therapeutic effect of the intended drug.
Consistent, continuous dosing of any product is necessary for optimal care for many ill patients. Patients should check with their health care provider regarding the appropriateness of their current therapy prior to making any change.
Please see this link for full details: http://www.upsher-smith.com/news/newsarticles/2011_02_18-Expanded-Recall.pdf